Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 3/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415823 | 0.91 | TNF (0.46) | CYP1A2CYP3A4CYP2C19TNF | |
| SCHEMBL14640120 | 0.84 | LMNA (0.52) | LMNAALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12968057 | 0.84 | GSK3A (0.44) | LMNAALDH1A1JAK1KDM4ESMN1; SMN2 | |
| SCHEMBL10264096 | 0.82 | JAK1 (0.42) | LMNAALDH1A1JAK1TNFKAT2B | |
| SCHEMBL16876309 | 0.82 | LMNA (0.42) | LMNAALDH1A1JAK1TNFKAT2B | |
| SCHEMBL16245549 | 0.82 | ALDH1A1 (0.48) | LMNAALDH1A1CYP1A2JAK1TNF | |
| SCHEMBL23321164 | 0.81 | ALDH1A1 (0.38) | LMNAALDH1A1L3MBTL1KDM4EHTT | |
| SCHEMBL19077876 | 0.81 | LMNA (0.41) | LMNAALDH1A1JAK1TNFKAT2B | |
| SCHEMBL10203198 | 0.79 | LMNA (0.40) | LMNAALDH1A1CYP2C19JAK1TNF | |
| SCHEMBL22566021 | 0.78 | LMNA (0.39) | LMNAALDH1A1JAK1TNFKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220220117-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2022-07-14 | — | — | US | disclosed |
| US-11312719-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2022-04-26 | — | — | US | disclosed |
| CN-113329791-A | 9-substituted amino-triazoloquinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and uses thereof | 默沙东公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210107904-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| WO-2020112700-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-06-04 | — | — | WO | disclosed |
| CN-104418866-B | Dgat1 inhibitor and its preparation method and application | 青岛黄海制药有限责任公司 | 2018-10-16 | — | — | CN | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
| CN-104418866-A | DGAT1 inhibitor, and preparation method and application thereof | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-03-18 | — | — | CN | disclosed |
| WO-2015024486-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京明德新药研发股份有限公司 (CN) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220117-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA3 | LMNA 2372/4885ALDH1A1 815/4885CYP1A2 146/4885 |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | LMNA 2372/4885ALDH1A1 815/4885CYP1A2 146/4885 |
| US-11312719-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | LMNA 2372/4885ALDH1A1 815/4885CYP1A2 146/4885 |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | DGAT1, DGAT2, LCAT | LMNA 2318/4885ALDH1A1 1707/4885CYP1A2 3066/4885 |
| US-20210107904-A1 | 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA3 | LMNA 2372/4885ALDH1A1 815/4885CYP1A2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.